|
1
|
Pastushenko I and Blanpain C: EMT
transition states during tumor progression and metastasis. Trends
Cell Biol. 29:212–226. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nieto MA, Huang RY, Jackson RA and Thiery
JP: EMT: 2016. Cell. 166:21–45. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fagotto F and Aslemarz A: EpCAM cellular
functions in adhesion and migration, and potential impact on
invasion: A critical review. Biochim Biophys Acta Rev Cancer.
1874:1884362020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
McDougall AR, Tolcos M, Hooper SB, Cole TJ
and Wallace MJ: Trop2: From development to disease. Dev Dyn.
244:99–109. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zaman S, Jadid H, Denson AC and Gray JE:
Targeting Trop-2 in solid tumors: Future prospects. Onco Targets
Ther. 12:1781–1790. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Goldenberg DM, Stein R and Sharkey RM: The
emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel
cancer target. Oncotarget. 9:28989–29006. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stepan LP, Trueblood ES, Hale K, Babcook
J, Borges L and Sutherland CL: Expression of Trop2 cell surface
glycoprotein in normal and tumor tissues: Potential implications as
a cancer therapeutic target. J Histochem Cytochem. 59:701–710.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
McDougall AR, Hooper SB, Zahra VA, Cole
TJ, Lo CY, Doran T and Wallace MJ: Trop2 regulates motility and
lamellipodia formation in cultured fetal lung fibroblasts. Am J
Physiol Lung Cell Mol Physiol. 305:L508–L521. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Akarken İ and Dere Y: Could trop-2
overexpression indicate tumor aggressiveness among prostatic
adenocarcinomas? Ann Diagn Pathol. 50:1516802021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen X, Pang B, Liang Y, Xu SC, Xin T, Fan
HT, Yu YB and Pang Q: Overexpression of EpCAM and Trop2 in
pituitary adenomas. Int J Clin Exp Pathol. 7:7907–7914.
2014.PubMed/NCBI
|
|
11
|
Li Z, Jiang X and Zhang W: TROP2
overexpression promotes proliferation and invasion of lung
adenocarcinoma cells. Biochem Biophys Res Commun. 470:197–204.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu N, Zhang Z, Zhu J, Xu L, Li Y, Duan L,
Mao Y and Li H: Overexpression of trophoblast cell surface antigen
2 as an independent marker for a poor prognosis and as a potential
therapeutic target in epithelial ovarian carcinoma. Int J Exp
Pathol. 97:150–158. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ambrogi F, Fornili M, Boracchi P,
Trerotola M, Relli V, Simeone P, La Sorda R, Lattanzio R, Querzoli
P, Pedriali M, et al: Trop-2 is a determinant of breast cancer
survival. PLoS One. 9:e969932014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhao W, Kuai X, Zhou X, Jia L, Wang J,
Yang X, Tian Z, Wang X, Lv Q, Wang B, et al: Trop2 is a potential
biomarker for the promotion of EMT in human breast cancer. Oncol
Rep. 40:759–766. 2018.PubMed/NCBI
|
|
15
|
Wang X, Long M, Dong K, Lin F, Weng Y,
Ouyang Y, Liu L, Wei J, Chen X, He T and Zhang HZ: Chemotherapy
agents-induced immunoresistance in lung cancer cells could be
reversed by trop-2 inhibition in vitro and in vivo by interaction
with MAPK signaling pathway. Cancer Biol Ther. 14:1123–1132. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sayama Y, Kaneko MK and Kato Y:
Development and characterization of TrMab-6, a novel anti-TROP2
monoclonal antibody for antigen detection in breast cancer. Mol Med
Rep. 23:922021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Itai S, Fujii Y, Nakamura T, Chang YW,
Yanaka M, Saidoh N, Handa S, Suzuki H, Harada H, Yamada S, et al:
Establishment of CMab-43, a sensitive and specific Anti-CD133
monoclonal antibody, for immunohistochemistry. Monoclon Antib
Immunodiagn Immunother. 36:231–235. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shvartsur A and Bonavida B: Trop2 and its
overexpression in cancers: Regulation and clinical/therapeutic
implications. Genes Cancer. 6:84–105. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang L, Zhou W, Velculescu VE, Kern SE,
Hruban RH, Hamilton SR, Vogelstein B and Kinzler KW: Gene
expression profiles in normal and cancer cells. Science.
276:1268–1272. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zeng P, Chen MB, Zhou LN, Tang M, Liu CY
and Lu PH: Impact of TROP2 expression on prognosis in solid tumors:
A systematic review and meta-analysis. Sci Rep. 6:336582016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gu QZ, Nijiati A, Gao X, Tao KL, Li CD,
Fan XP and Tian Z: TROP2 promotes cell proliferation and migration
in osteosarcoma through PI3K/AKT signaling. Mol Med Rep.
18:1782–1788. 2018.PubMed/NCBI
|
|
22
|
Shaffer C: Trop2 deal heats up
antibody-drug conjugate space in cancer. Nat Biotechnol.
39:128–130. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Seligson JM, Patron AM, Berger MJ, Harvey
RD and Seligson ND: Sacituzumab Govitecan-hziy: An antibody-drug
conjugate for the treatment of refractory, metastatic,
triple-negative breast cancer. Ann Pharmacother. Oct 17–2020.(Epub
ahead of print). doi: 10.1177/1060028020966548. PubMed/NCBI
|
|
24
|
Authors not listed. TROP2 ADC Intrigues in
NSCLC. Cancer Discov. 11:OF52021. View Article : Google Scholar
|
|
25
|
Son S, Shin S, Rao NV, Um W, Jeon J, Ko H,
Deepagan VG, Kwon S, Lee JY and Park JH: Anti-Trop2
antibody-conjugated bioreducible nanoparticles for targeted triple
negative breast cancer therapy. Int J Biol Macromol. 110:406–415.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Crystal AS, Shaw AT, Sequist LV, Friboulet
L, Niederst MJ, Lockerman EL, Frias RL, Gainor JF, Amzallag A,
Greninger P, et al: Patient-derived models of acquired resistance
can identify effective drug combinations for cancer. Science.
346:1480–1486. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Beck A, Goetsch L, Dumontet C and Corvaia
N: Strategies and challenges for the next generation of
antibody-drug conjugates. Nat Rev Drug Discov. 16:315–337. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yamada S, Kaneko MK, Sayama Y, Asano T,
Sano M, Yanaka M, Nakamura T, Okamoto S, Handa S, Komatsu Y, et al:
Development of novel mouse monoclonal antibodies against human
CD19. Monoclon Antib Immunodiagn Immunother. 39:45–50. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Furusawa Y, Kaneko MK and Kato Y:
Establishment of C20Mab-11, a novel anti-CD20 monoclonal
antibody, for the detection of B cells. Oncol Lett. 20:1961–1967.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yamada S, Itai S, Nakamura T, Yanaka M,
Kaneko MK and Kato Y: Detection of high CD44 expression in oral
cancers using the novel monoclonal antibody, C44Mab-5.
Biochem Biophys Rep. 14:64–68. 2018.PubMed/NCBI
|
|
31
|
Hosono H, Ohishi T, Takei J, Asano T,
Sayama Y, Kawada M, Kaneko MK and Kato Y: The anti-epithelial cell
adhesion molecule (EpCAM) monoclonal antibody EpMab-16 exerts
antitumor activity in a mouse model of colorectal adenocarcinoma.
Oncol Lett. 20:3832020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kato Y, Ohishi T, Yamada S, Itai S,
Furusawa Y, Sano M, Nakamura T, Kawada M and Kaneko MK: Anti-CD133
monoclonal antibody CMab-43 exerts antitumor activity in a mouse
xenograft model of colon cancer. Monoclon Antib Immunodiagn
Immunother. 38:75–78. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kaneko MK, Ohishi T, Takei J, Sano M,
Nakamura T, Hosono H, Yanaka M, Asano T, Sayama Y, Harada H, et al:
Anti-EpCAM monoclonal antibody exerts antitumor activity against
oral squamous cell carcinomas. Oncol Rep. 44:2517–2526. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Takei J, Kaneko MK, Ohishi T, Hosono H,
Nakamura T, Yanaka M, Sano M, Asano T, Sayama Y, Kawada M, et al: A
defucosylated anti-CD44 monoclonal antibody 5-mG2a-f exerts
antitumor effects in mouse xenograft models of oral squamous cell
carcinoma. Oncol Rep. 44:1949–1960. 2020.PubMed/NCBI
|
